Trial Profile
BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms BEACON
- 04 Aug 2023 Planned End Date changed from 28 Feb 2024 to 30 Jun 2025.
- 04 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 28 Feb 2024.
- 04 Aug 2023 Status changed from recruiting to active, no longer recruiting.